About Boston Scientific
Boston Scientific (NYSE: BSX) is a leading global healthcare company with approximately 29,000 employees and revenue of $9 billion.

Mission
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Important numbers at a glance (as of March 30, 2018)
• One of the world’s largest medical device companies
• 19,000+ patents issued
• $1 billion invested in R&D
• ~ 29000 employees worldwide
• Market presence in approximately 125 countries worldwide

Businesses
For more than 35 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties.

- Interventional Cardiology
- Rhythm Management
- Endoscopy
- Neuromodulation
- Peripheral Interventions
- Urology and Pelvic Health

In addition to providing technologies that improve patient outcomes, we also help customers to achieve and sustain cost, quality and growth targets thanks to our ADVANTICSTM Innovative Healthcare Solutions portfolio.

Locations
• Global corporate HQ: Marlborough, Massachusetts (USA)
• Regional HQs: Singapore and Paris
• Major technology centres: Minnesota, California, Ireland, Costa Rica
• 13 manufacturing facilities worldwide
• 9 Institutes for Advancing Science in the Americas, Africa, Asia and Europe.

Select Senior Leadership1
• Chairman of the Board; President and Chief Executive Officer: Michael F. Mahoney
• Executive Vice President and Chief Financial Officer: Daniel J. Brennan
• Senior Vice President, General Counsel and Corporate Secretary: Desiree Ralls-Morrison
• Senior Vice President and President, Europe, Middle East and Africa: Eric Thépaut
• Senior Vice President and President, Asia Pacific: Warren Wang

---

Financials:
• $9.048 billion revenue in 2017
• 7% organic revenue growth in 2017\(^2\)
• 13% adjusted EPS in 2017\(^2\)
• 480 adjusted operating margin basis point improvement since 2014
• NYSE: BSX

Annual Report
Boston Scientific annual report and financial statement 2017 available here

Contact information
For further information, contact us at EMEA.MediaRelations@bsci.com, visit www.bostonscientific.eu and our Twitter Handles: @BSC_EU_Heart, @BSCNeuromodEU, @BSC_Spain, BSC_Neuromod

\(^2\) Non-GAAP measure; excludes certain GAAP items. For reconciliations of non-GAAP financial measures to the most directly comparable GAAP figures, please refer to our Financial Disclaimers and Non-GAAP Reconciliations.